![Hummingbird Bioscience on Twitter: "#HummingbirdBioscience announces first patient has been dosed in a Phase 1 clinical trial of HMBD-001 for the treatment of patients with advanced HER3 expressing solid malignancies. The trial Hummingbird Bioscience on Twitter: "#HummingbirdBioscience announces first patient has been dosed in a Phase 1 clinical trial of HMBD-001 for the treatment of patients with advanced HER3 expressing solid malignancies. The trial](https://pbs.twimg.com/media/FF6j227VgAMRALA.jpg:large)
Hummingbird Bioscience on Twitter: "#HummingbirdBioscience announces first patient has been dosed in a Phase 1 clinical trial of HMBD-001 for the treatment of patients with advanced HER3 expressing solid malignancies. The trial
![Hummingbird Bioscience Exercises Its Option to License the Clinical Trial Results from Cancer Research UK to Support Further Development of HMBD-001 Hummingbird Bioscience Exercises Its Option to License the Clinical Trial Results from Cancer Research UK to Support Further Development of HMBD-001](https://mma.prnewswire.com/media/1962239/Hummingbird_Logo.jpg)
Hummingbird Bioscience Exercises Its Option to License the Clinical Trial Results from Cancer Research UK to Support Further Development of HMBD-001
![Hummingbird Bioscience Announces Collaboration with Tempus to Harness AI-driven Precision Medicine to Accelerate Clinical Development of HMBD-001 In HER3 Driven Cancers Hummingbird Bioscience Announces Collaboration with Tempus to Harness AI-driven Precision Medicine to Accelerate Clinical Development of HMBD-001 In HER3 Driven Cancers](https://mma.prnewswire.com/media/1384630/Hummingbird_Bioscience_Logo.jpg)